"MAP Kinase Kinase 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An abundant 43-kDa mitogen-activated protein kinase kinase subtype with specificity for MITOGEN-ACTIVATED PROTEIN KINASE 1 and MITOGEN-ACTIVATED PROTEIN KINASE 3.
| Descriptor ID |
D048369
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.565.100 D08.811.913.696.620.682.725.200.100 D12.644.360.440.100 D12.776.476.440.100
|
| Concept/Terms |
MAP Kinase Kinase 1- MAP Kinase Kinase 1
- MKK1 Protein Kinase
- MAP2K1 Protein
- Mitogen-Activated Protein Kinase Kinase 1
- Mitogen Activated Protein Kinase Kinase 1
- MKK-1 Protein Kinase
- MKK 1 Protein Kinase
- MEK-1 Protein Kinase
- MEK 1 Protein Kinase
- MAPK Kinase 1
- MEK1 Protein Kinase
|
Below are MeSH descriptors whose meaning is more general than "MAP Kinase Kinase 1".
Below are MeSH descriptors whose meaning is more specific than "MAP Kinase Kinase 1".
This graph shows the total number of publications written about "MAP Kinase Kinase 1" by people in this website by year, and whether "MAP Kinase Kinase 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 3 | 3 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "MAP Kinase Kinase 1" by people in Profiles.
-
Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. Leuk Lymphoma. 2018 04; 59(4):1008-1011.
-
Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors. Oncotarget. 2016 Feb 02; 7(5):5306-12.
-
Activation of ERK accelerates repair of renal tubular epithelial cells, whereas it inhibits progression of fibrosis following ischemia/reperfusion injury. Biochim Biophys Acta. 2013 Dec; 1832(12):1998-2008.
-
17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species. Mol Cancer Ther. 2010 May; 9(5):1378-95.
-
MEK1 activation by PAK: a novel mechanism. Cell Signal. 2007 Jul; 19(7):1488-96.
-
Gene expression profiling following constitutive activation of MEK1 and transformation of rat intestinal epithelial cells. Mol Cancer. 2006 Nov 17; 5:63.
-
Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria. Mol Cancer Res. 2006 Aug; 4(8):549-62.
-
Oncogenic potential of MEK1 in rat intestinal epithelial cells is mediated via cyclooxygenase-2. Gastroenterology. 2005 Aug; 129(2):577-90.
-
Inhibition of phosphatidylinostol 3-kinase uncouples H2O2-induced senescent phenotype and cell cycle arrest in normal human diploid fibroblasts. Exp Cell Res. 2004 Aug 01; 298(1):188-96.
-
ERK and MMPs sequentially regulate distinct stages of epithelial tubule development. Dev Cell. 2004 Jul; 7(1):21-32.